Summary Background The cardiovascular-kidney-liver-metabolic (CKLM) framework represents the multi-organ interplay of systemic metabolic disorders that drive the global burden of cardiovascular diseases (CVD). Methods This study is a descriptive epidemiological analysis of the Global Burden of Disease Study 2023 that e...
J. Jayabaskaran, Haryo Raden Himan, S. Nagarajan et al.· EClinicalMedicine· 0 citations
This review examines the role of elevated Lp(a) in premature cardiovascular events, including premature myocardial infarction, stroke, and peripheral arterial disease, and highlights the importance Lp(a) testing may play in secondary prevention, focusing on cascade screening for elevated Lp(a) in relatives of affected...
M. Safarova, Laurence S. Sperling, Anurag Mehta et al.· European Journal of Preventi...· 0 citations
Observational research and post-hoc analyses suggest that aspirin use may be associated with lower ASCVD risk among individuals with elevated Lp(a), supporting an individualized, shared decision-making approach that considers bleeding risk, overall cardiovascular risk profile, and additional markers of cardiovascular r...
Jeffery Osei, Josiah Bennett, Om Raval et al.· Current Treatment Options in...· 0 citations
Individuals with MASLD who experience a CVD event have a higher subsequent risk of long-term LREs, and the value of targeted liver monitoring for high-risk individuals after CVD and integrated heart-liver co-management is underscored.
Li-You Lian, Qin-Fen Chen, Tianyi Xia et al.· Metabolism: Clinical and Exp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.